Cargando…

How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists

The coronavirus disease 2019 (COVID-19) pandemic due to infection by a new human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seriously disrupted the provision of oncology services and their uptake. Antibody testing, both at an individual level and of populations, h...

Descripción completa

Detalles Bibliográficos
Autores principales: Maple, P.A.C., Sikora, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal College of Radiologists. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553121/
https://www.ncbi.nlm.nih.gov/pubmed/33350940
http://dx.doi.org/10.1016/j.clon.2020.10.008
_version_ 1783593539669590016
author Maple, P.A.C.
Sikora, K.
author_facet Maple, P.A.C.
Sikora, K.
author_sort Maple, P.A.C.
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic due to infection by a new human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seriously disrupted the provision of oncology services and their uptake. Antibody testing, both at an individual level and of populations, has been widely viewed to be a key activity for guiding the options for treatment of high-risk individuals, as well as the implementation of safe control of infection measures. Ideally, the detection of a specific antibody should signify that all individuals tested have been infected by SARS-CoV-2 and that in the case of specific IgG that they are immune to further infection. This would enable SARS-CoV-2-infected individuals to be appropriately managed and healthcare workers shown to be immune to return to work where they would no longer pose a risk to their patients or be at risk themselves. Unfortunately, this is not the case for COVID-19, where it has been shown that immunity may not be protective, and seroconversion delayed or absent. The variability in antibody test performance, particularly that of lateral flow assays, has caused confusion for the public and healthcare professions alike. Many antibody test devices have been made available without independent evaluations and these may lack both adequate sensitivity and specificity. This review seeks to educate healthcare workers, particularly those working in oncology, of the current benefits and limitations of SARS-CoV-2 antibody testing.
format Online
Article
Text
id pubmed-7553121
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Royal College of Radiologists. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75531212020-10-13 How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists Maple, P.A.C. Sikora, K. Clin Oncol (R Coll Radiol) Overview The coronavirus disease 2019 (COVID-19) pandemic due to infection by a new human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seriously disrupted the provision of oncology services and their uptake. Antibody testing, both at an individual level and of populations, has been widely viewed to be a key activity for guiding the options for treatment of high-risk individuals, as well as the implementation of safe control of infection measures. Ideally, the detection of a specific antibody should signify that all individuals tested have been infected by SARS-CoV-2 and that in the case of specific IgG that they are immune to further infection. This would enable SARS-CoV-2-infected individuals to be appropriately managed and healthcare workers shown to be immune to return to work where they would no longer pose a risk to their patients or be at risk themselves. Unfortunately, this is not the case for COVID-19, where it has been shown that immunity may not be protective, and seroconversion delayed or absent. The variability in antibody test performance, particularly that of lateral flow assays, has caused confusion for the public and healthcare professions alike. Many antibody test devices have been made available without independent evaluations and these may lack both adequate sensitivity and specificity. This review seeks to educate healthcare workers, particularly those working in oncology, of the current benefits and limitations of SARS-CoV-2 antibody testing. The Royal College of Radiologists. Published by Elsevier Ltd. 2021-01 2020-10-13 /pmc/articles/PMC7553121/ /pubmed/33350940 http://dx.doi.org/10.1016/j.clon.2020.10.008 Text en © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Overview
Maple, P.A.C.
Sikora, K.
How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists
title How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists
title_full How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists
title_fullStr How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists
title_full_unstemmed How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists
title_short How Useful is COVID-19 Antibody Testing – A Current Assessment for Oncologists
title_sort how useful is covid-19 antibody testing – a current assessment for oncologists
topic Overview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553121/
https://www.ncbi.nlm.nih.gov/pubmed/33350940
http://dx.doi.org/10.1016/j.clon.2020.10.008
work_keys_str_mv AT maplepac howusefuliscovid19antibodytestingacurrentassessmentforoncologists
AT sikorak howusefuliscovid19antibodytestingacurrentassessmentforoncologists